Event-Free Survival
FIG 3. · Panel C
Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R Broderick, Scott J Swanson, Julie Brahmer, Keith Kerr, Gene B Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, Mariano Provencio Pulla
J Clin Oncol 43(12) 1453-1462
PURPOSE: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial. METHODS: Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery. Analyses included event-free survival (EFS), OS, pathologic response, surgical outcomes, biomarker analyses, and safety. RESULTS: A total of 221 patients were concurrently randomly assigned to nivolumab plus ipilimumab (n = 113) or chemotherapy (n = 108). At a median follow-up of 49.2 months, the median EFS was 54.8 months (95% CI, 24.4 to not reached [NR]) with nivolumab plus ipilimumab versus 20.9 months (95% CI, 14.2 to NR) with chemotherapy (HR, 0.77 [95% CI, 0.51 to 1.15]); 3-year EFS rates were 56% versus 44%. Higher rates of EFS events were initially seen, with later benefit favoring nivolumab plus ipilimumab; 3-year OS rates were 73% versus 61% (HR, 0.73 [95% CI, 0.47 to 1.14]); pathologic complete response rates were 20.4% versus 4.6%, respectively. In the respective arms, 83 (74%) and 82 patients (76%) underwent definitive surgery. Grade 3-4 treatment-related adverse events occurred in 14% and 36% of patients, respectively. CONCLUSION: Neoadjuvant nivolumab plus ipilimumab showed potential long-term clinical benefit versus chemotherapy, despite early crossing of EFS curves in the preoperative phase and a lower rate of high-grade toxicity.
1 个 Figure · 2 个 KM 面板
Baseline four-gene inflammatory signature score by (A) pCR, (B) MPR, and (C) EFS in the nivolumab plus ipilimumab arm and (D) EFS in the chemotherapy arm. The four-gene inflammatory signature comprised CD8A , STAT1 , LAG3 , and CD274 (encoding PD-L1) 15 and was assessed by RNA sequencing of evaluable tumor samples at baseline; scores were grouped as high or low relative to the median z -score across the data set. pCR (0% RVT) and MPR (≤10% RVT) postsurgery in both primary tumor (lung) and sampled lymph nodes per BIPR. EFS was per BICR. Patients who received subsequent therapy were censored at the last evaluable tumor assessment on or before the date of subsequent therapy. BICR, blinded independent central review; BIPR, blinded independent pathologic review; EFS, event-free survival; HR, hazard ratio; MPR, major pathologic response; NR, not reached; pCR, pathologic complete response; RVT, residual viable tumor.
FIG 3. · Panel C
Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. · Panel D
Panel D 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。